Advanced search
Publication Cover
Infection and Drug Resistance Volume 17, 2024 - Issue
Submit an article Journal homepage
98
Views
0
CrossRef citations to date
0
Altmetric
CASE REPORT

Contezolid-Containing Regimen Successfully Treated Multiple Drug Resistance Mycobacterium Abscessus Complex Infection of Skin: A Case Report and Literature Review

Xusheng GaoDepartment of Tuberculosis, Shandong Public Health Clinical Center, Shandong University, Jinan, Shandong, People’s Republic of ChinaView further author information
,
Caihong DingDepartment of Tuberculosis, Shandong Public Health Clinical Center, Shandong University, Jinan, Shandong, People’s Republic of ChinaView further author information
,
Dan XieDepartment of Tuberculosis, Shandong Public Health Clinical Center, Shandong University, Jinan, Shandong, People’s Republic of ChinaView further author information
,
Qing WangDepartment of Tuberculosis, Shandong Public Health Clinical Center, Shandong University, Jinan, Shandong, People’s Republic of ChinaView further author information
,
Peipei JiangDepartment of Tuberculosis, Shandong Public Health Clinical Center, Shandong University, Jinan, Shandong, People’s Republic of ChinaView further author information
,
Yuyu WangDepartment of Tuberculosis, Shandong Public Health Clinical Center, Shandong University, Jinan, Shandong, People’s Republic of ChinaView further author information
&
Yu XiongDepartment of Tuberculosis, Shandong Public Health Clinical Center, Shandong University, Jinan, Shandong, People’s Republic of ChinaCorrespondence[email protected]
View further author information
 show all
Pages 1243-1249 | Received 06 Dec 2023, Accepted 13 Mar 2024, Published online: 27 Mar 2024

References

  • Winthrop KL, Marras TK, Adjemian J, et al. Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S. managed care health plan. Ann Am Thorac Soc. 2020;17(2):178–185. doi:10.1513/AnnalsATS.201804-236OC
  • Suresh P, Kumar A, Biswas R, et al. Epidemiology of nontuberculous mycobacterial infection in tuberculosis suspects. Am J Trop Med Hyg. 2021;105(5):1335–1338. doi:10.4269/ajtmh.21-0095
  • Kumar K, Loebinger MR. Nontuberculous mycobacterial pulmonary disease: clinical epidemiologic features, risk factors, and diagnosis: the nontuberculous mycobacterial series. Chest. 2022;161(3):637–646. doi:10.1016/j.chest.2021.10.003
  • Li W, Yazidi A, Pandya AN, et al. MmpL3 as a target for the treatment of drug-resistant nontuberculous mycobacterial infections. Front Microbiol. 2018;9:1547. doi:10.3389/fmicb.2018.01547
  • Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020;56(1):2000535. doi:10.1183/13993003.00535-2020
  • Uslan DZ, Kowalski TJ, Wengenack NL, et al. Skin and soft tissue infections due to rapidly growing mycobacteria: comparison of clinical features, treatment, and susceptibility. Arch Dermatol. 2006;142(10):1287–1292. doi:10.1001/archderm.142.10.1287
  • Raju RM, Raju SM, Zhao Y, et al. Leveraging advances in tuberculosis diagnosis and treatment to address nontuberculous mycobacterial disease. Emerg Infect Dis. 2016;22(3):365–369. doi:10.3201/eid2203.151643
  • Diel R, Nienhaus A, Ringshausen FC, et al. Microbiologic outcome of interventions against mycobacterium avium complex pulmonary disease: a systematic review. Chest. 2018;153(4):888–921. doi:10.1016/j.chest.2018.01.024
  • Diel R, Lipman M, Hoefsloot W. High mortality in patients with mycobacterium avium complex lung disease: a systematic review. BMC Infect Dis. 2018;18(1):206. doi:10.1186/s12879-018-3113-x
  • Haworth CS, Banks J, Capstick Tet al. British thoracic society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72(Suppl 2):969–970. doi:10.1136/thoraxjnl-2017-210929
  • Wu J, Lu AD, Zhang LP, et al. Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia. Zhonghua Xue Ye Xue Za Zhi. 2019;40(1):52–57. doi:10.3760/cma.j.issn.0253-2727.2019.01.010
  • Li CR, Zhai QQ, Wang XK, et al. In vivo antibacterial activity of MRX-I, a new oxazolidinone. Antimicrob Agents Chemother. 2014;58(4):2418–2421. doi:10.1128/AAC.01526-13
  • Eckburg PB, Ge Y, Hafkin B. Single- and multiple-dose study to determine the safety, tolerability, pharmacokinetics, and food effect of oral MRX-I versus linezolid in healthy adult subjects. Antimicrob Agents Chemother. 2017;61(4). doi:10.1128/AAC.02181-16
  • Guo Q, Xu L, Tan F, et al. a novel oxazolidinone, contezolid (MRX-I), expresses anti-mycobacterium abscessus activity in vitro. Antimicrob Agents Chemother. 2021;65(11):e0088921. doi:10.1128/AAC.00889-21
  • Ratnatunga CN, Lutzky VP, Kupz A, et al. The rise of non-tuberculosis mycobacterial lung disease. Front Immunol. 2020;11:303. doi:10.3389/fimmu.2020.00303
  • Rabon AD, Fisher JP, MacVane SH. Incidence and risk factors for development of thrombocytopenia in patients treated with linezolid for 7 days or greater. Ann Pharmacother. 2018;52(11):1162–1164. doi:10.1177/1060028018783498
  • Huang JW, Kuo CL, Wang LT, et al. Case report: in situ vaccination by autologous CD16(+) dendritic cells and anti-PD-L 1 antibody synergized with radiotherapy to boost T cells-mediated antitumor efficacy in a psoriatic patient with cutaneous squamous cell carcinoma. Front Immunol. 2021;12:752563. doi:10.3389/fimmu.2021.752563
  • Gordeev MF, Yuan ZY. New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile. J Med Chem. 2014;57(11):4487–4497. doi:10.1021/jm401931e
  • Morelli T, Fujita K, Redelman-Sidi G, et al. Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy. Thorax. 2022;77(3):304–311. doi:10.1136/thoraxjnl-2021-217260
  • Zhao X, Huang H, Yuan H, et al. A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections. J Antimicrob Chemother. 2022;77(6):1762–1769. doi:10.1093/jac/dkac073
  • Meng J, Zhong D, Li L, et al. Metabolism of MRX-I, a novel antibacterial oxazolidinone, in humans: the oxidative ring opening of 2,3-dihydropyridin-4-one catalyzed by non-P450 enzymes. Drug Metab Dispos. 2015;43(5):646–659. doi:10.1124/dmd.114.061747

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.